Moderna wins patent lawsuit against BioNTech/Pfizer
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results